Monte Rosa Therapeutics (NASDAQ:GLUE) Shares Gap Down – Should You Sell?

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) gapped down before the market opened on Friday . The stock had previously closed at $22.68, but opened at $15.47. Monte Rosa Therapeutics shares last traded at $15.3760, with a volume of 1,792,830 shares changing hands.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the stock. Weiss Ratings upgraded shares of Monte Rosa Therapeutics from a “sell (d)” rating to a “sell (d+)” rating in a research note on Tuesday. Zacks Research cut shares of Monte Rosa Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Monday, July 6th. JPMorgan Chase & Co. lifted their price target on shares of Monte Rosa Therapeutics from $30.00 to $31.00 and gave the company an “overweight” rating in a report on Monday, May 11th. Guggenheim boosted their price target on shares of Monte Rosa Therapeutics from $30.00 to $35.00 and gave the company a “buy” rating in a research report on Tuesday, June 30th. Finally, Jefferies Financial Group reaffirmed a “buy” rating on shares of Monte Rosa Therapeutics in a research note on Monday. Seven equities research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $34.83.

Monte Rosa Therapeutics Price Performance

The company has a market cap of $1.35 billion, a price-to-earnings ratio of -10.84 and a beta of 1.56. The business has a 50 day simple moving average of $20.93 and a 200 day simple moving average of $19.65.

Monte Rosa Therapeutics (NASDAQ:GLUE) last announced its earnings results on Thursday, May 7th. The company reported ($0.45) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.06). Monte Rosa Therapeutics had a negative net margin of 302.69% and a negative return on equity of 40.99%. The business had revenue of $4.21 million during the quarter, compared to analyst estimates of $10.95 million. As a group, sell-side analysts anticipate that Monte Rosa Therapeutics, Inc. will post -1.23 earnings per share for the current fiscal year.

Insider Activity at Monte Rosa Therapeutics

In other Monte Rosa Therapeutics news, COO Jennifer Champoux sold 2,175 shares of the stock in a transaction dated Tuesday, June 23rd. The shares were sold at an average price of $20.00, for a total transaction of $43,500.00. Following the sale, the chief operating officer owned 62,371 shares of the company’s stock, valued at $1,247,420. This represents a 3.37% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Sharon Townson sold 6,000 shares of the firm’s stock in a transaction dated Monday, July 6th. The shares were sold at an average price of $23.31, for a total transaction of $139,860.00. Following the completion of the sale, the insider owned 67,845 shares of the company’s stock, valued at $1,581,466.95. The trade was a 8.13% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 81,778 shares of company stock worth $1,768,581 in the last quarter. Insiders own 6.40% of the company’s stock.

Institutional Trading of Monte Rosa Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. State Street Corp boosted its position in Monte Rosa Therapeutics by 148.9% in the 4th quarter. State Street Corp now owns 2,107,480 shares of the company’s stock valued at $33,045,000 after buying an additional 1,260,707 shares during the last quarter. MPM Bioimpact LLC bought a new stake in shares of Monte Rosa Therapeutics during the fourth quarter worth $18,399,000. AQR Capital Management LLC raised its position in shares of Monte Rosa Therapeutics by 459.4% during the second quarter. AQR Capital Management LLC now owns 1,283,942 shares of the company’s stock worth $5,791,000 after acquiring an additional 1,054,406 shares during the last quarter. Braidwell LP acquired a new position in shares of Monte Rosa Therapeutics during the fourth quarter valued at $14,870,000. Finally, Vestal Point Capital LP acquired a new position in shares of Monte Rosa Therapeutics during the third quarter valued at $5,928,000. Institutional investors and hedge funds own 79.96% of the company’s stock.

Monte Rosa Therapeutics Company Profile

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.